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Abstract
Background: Although endemic cholera causes significant morbidity and mortality each year in Nepal, lack of
information about the causal bacterium often hinders cholera intervention and prevention. In 2012, diarrheal
outbreaks affected three districts of Nepal with confirmed cases of mortality. This study was designed to understand
the drug response patterns, source, and transmission of Vibrio cholerae associated with 2012 cholera outbreaks
in Nepal.
Methods: V. cholerae (n = 28) isolated from 2012 diarrhea outbreaks {n = 22; Kathmandu (n = 12), Doti (n = 9),
Bajhang (n = 1)}, and surface water (n = 6; Kathmandu) were tested for antimicrobial response. Virulence properties and
DNA fingerprinting of the strains were determined by multi-locus genetic screening employing polymerase chain
reaction, DNA sequencing, and pulsed-field gel electrophoresis (PFGE).
Results: All V. cholerae strains isolated from patients and surface water were confirmed to be toxigenic, belonging to
serogroup O1, Ogawa serotype, biotype El Tor, and possessed classical biotype cholera toxin (CTX). Double-mismatch
amplification mutation assay (DMAMA)-PCR revealed the V. cholerae strains to possess the B-7 allele of ctx subunit
B. DNA sequencing of tcpA revealed a point mutation at amino acid position 64 (N→ S) while the ctxAB promoter
revealed four copies of the tandem heptamer repeat sequence 5'-TTTTGAT-3'. V. cholerae possessed all the ORFs of the
Vibrio seventh pandemic island (VSP)-I but lacked the ORFs 498–511 of VSP-II. All strains were multidrug resistant with
resistance to trimethoprim-sulfamethoxazole (SXT), nalidixic acid (NA), and streptomycin (S); all carried the SXT genetic
element. DNA sequencing and deduced amino acid sequence of gyrA and parC of the NAR strains (n = 4) revealed
point mutations at amino acid positions 83 (S→ I), and 85 (S→ L), respectively. Similar PFGE (NotI) pattern revealed the
Nepalese V. cholerae to be clonal, and related closely with V. cholerae associated with cholera in Bangladesh and Haiti.
Conclusions: In 2012, diarrhea outbreaks in three districts of Nepal were due to transmission of multidrug resistant V.
cholerae El Tor possessing cholera toxin (ctx) B-7 allele, which is clonal and related closely with V. cholerae associated
with cholera in Bangladesh and Haiti.
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Background
Toxigenic Vibrio cholerae is the causative agent of cholera,
an acute life-threatening diarrheal disease, which occurs
in many developing countries, particularly South Asia,
Africa, and Latin America [1,2]. Based on the phenotypic
and genotypic differences,V. cholerae O1 strains are clas-
sified into two biotypes: ‘classical’ and ‘El Tor’ [3]. Seven
distinct pandemics of cholera have been recorded since
1817 [4]. The sixth pandemic, and presumably the earlier
pandemics, were caused by the classical biotype of V.
cholerae O1, which was displaced by V. cholerae O1
biotype El Tor in the 1960’s to become the causative
agent of the ongoing seventh cholera pandemic [1].
Over the past few years, V. cholerae O1 biotype ET
causing Asiatic cholera has shown remarkable changes in
its phenotypic and genetic characteristics [5]. V. cholerae
O139, also known as Bengal strain emerged in 1992 as
the major cause of epidemic cholera in Bangladesh and
India by displacing ET biotype strains [6]. V. cholerae O1
ET continues to prevail as the major cause of cholera
worldwide. The most recent development in the evolution
of global cholera has been the emergence and spread of a
new variant ET, or altered ET, in Bangladesh that carries
ctxB of the classical (CL) biotype (ctxBCL) [7]. Since 2001,
V. cholerae O1 biotype ET strains associated with endemic
cholera in Bangladesh have been altered ET, while those
isolated before 2001 contained ctxB of the ET biotype [7],
which is the prototype associated with the 7th cholera
pandemic. According to recent reports, altered ET strains
have been spreading globally [8-15] causing more severe
disease [16].
Following the earthquake in Haiti in 2010, epidemic
cholera broke out in the country that has since affected
tens of thousands of people and led to the death of
more than 4,000 [17]. Although the 7th cholera pandemic
expanded from Asia reaching Africa in the 1970’s and
Latin America in 1991, cholera had never been reported
in Haiti after 1960 [18]. The source of the recent cholera
epidemic in Haiti remains controversial but it is widely
believed that it was imported by UN peacekeeping forces
arriving from Nepal [17,19].
Nepal is a cholera endemic country where cholera
continues to be a major public health concern, especially
among lower socio-economic groups. Although cholera
causes significant morbidity and mortality each year,
Nepal lacks the requisite laboratory infrastructures to
conduct epidemiological and related surveillance to
determine disease burden, as well as to identify the
source and transmission of cholera. Both of these types of
information are important for the effective management
of all infectious diseases, not only cholera and diarrhea. In
2012, outbreaks of cholera were reported in three districts
of Nepal with death of some of the affected individuals
in remote villages in the north-western district of Doti.
Cholera treatment is often hindered due to emergence of
multi-drug resistance in V. cholerae [20,21]. Compound-
ing the problem related to selecting an effective antibiotic
for cholera treatments, even less is known about drug
resistance properties of V. cholerae O1 bacterium in Nepal
[22-25]. In the present study,V. cholerae strains associated
with the 2012 cholera outbreaks in three district of Nepal
were investigated for microbiological and molecular
characteristics. The major tests applied to this study
included antibiotic response patterns, and multi-locus
genetic screening by polymerase chain reaction, DNA
fingerprinting analyses by sequencing, and pulsed-field
gel electrophoresis (PFGE) of genomic DNA.
Methods
Ethical approval
Ethical approval for the present study was obtained from
the Ethical Review Board of Nepal Health Research
Council (NHRC) (Reg. 68/2011; 2068-12-20 approved
on 2 April 2012). Informed consent was obtained for all
patients enrolled in the present study, for patients under
18 years of age parental consent was obtained.
Isolation of V. cholerae
During the 2012 cholera outbreaks in three districts of
Nepal (Figure 1), V. cholerae isolated from clinical
[Kathmandu (n = 12), Doti (n = 9), and Bajhang (n = 1)] and
natural surface water [Kathmandu (n = 6)] sources were
confirmed by microbiological, serological and molecular
methods. V. cholerae isolation involved enriching the
samples in alkaline peptone water (APW) (pH-8.4) at 37°C
for 4–6 h, followed by culturing overnight on selective
bacteriological media such as taurocholate tellurite gelatin
agar (TTGA). V. cholerae colonies were confirmed using
a combination of biochemical and serological methods,
as described previously [26]. V. cholerae isolates were
examined for phenotypic test such as antimicrobial
response, as well as for virulence, molecular, and phylo-
genetic characteristics. Reference V. cholerae O1 strains
N16961 and O395 served as biotypes El Tor (ET) and
Classical (CL) control, respectively.
Determination of serogroup and biotype
Serogroups of the V. cholerae isolates were identified
by biochemical and molecular methods and confirmed
by slide agglutination using specific polyvalent antisera
for V. cholerae O1 and O139, followed by screening with a
monoclonal antibody specific for both serogroups [26].
Biotyping primarily involved selective phenotypic tests,
including chicken erythrocyte agglutination, sensitivity to
polymyxin B, and Mukherjee CL phage IV and Mukherjee
ET phage V [1].
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Genomic DNA preparation
Genomic DNA extraction was carried out following pre-
viously described methods [11].
PCR assays for serogroup and biotype determination
Subtypes of all strains were reconfirmed using V. cholerae
species-specific ompW PCR [27]. Serogroups were recon-
firmed using multiplex PCR targeted at O1- (rfbO1) and
O139- (rfbO139) specific O biosynthetic genes and the
cholera toxin (CTX) gene (ctxA) [28]. Biotype specific
characteristics were determined using PCR assays targeted
to tcpA (CL and ET) [29], rstR, a gene encoding phage
transcriptional regulator [30], presence of the repeat in
toxin (rtxC) [31], rstC that encodes an anti-repressor
protein, and tlc, that codes for the toxin-linked cryptic
plasmid [32].
Determination of ctxB genotype
The double mismatch amplification mutation assay
(DMAMA-PCR) was recently developed to discriminate
the classical (ctxB genotype 1), El Tor (ctxB gneotype
3), and Haitian types (ctxB genotype 7) of ctxB alleles
by focusing on nucleotide positions 58 and 203 of the
ctxB gene [33]. DMAMA-PCR was performed in this
study to detect the ctxB genotype using primers and
conditions as described previously [33]. V. cholerae O1
strains O395 (CL), N16961 (ET), and 2010EL-1786
(Haiti variant, genotype 7) were used as control strains
for DMAMA-PCR analysis.
Nucleotide sequencing and analysis of genes ctxB and tcpA
Genes ctxB and tcpA of randomly selected V. cholerae
O1 strains in 2012 were sequenced following conditions
as described elsewhere [34]. PCR amplification of genes
ctxB and tcpA was performed in a 25 μl reaction mixture
in an automated Peltier thermal cycler (PTC-200, M. J.
Research). Subsequently, PCR products were purified with
a Microcon centrifugal filter device (Millipore Corporation,
Bedford, MA) and sequenced using an ABI PRISM Big
Dye Terminator Cycle Sequencing Reaction kit (Applied
Biosystems, Foster City, CA) on an ABI PRISM 310
automated sequencer (Applied Biosystems). The deduced
amino acid sequences of the respective genes from all
strains were aligned using CLUSTAL-W.
The promoter sequence of ctxABclass operon
The 600 bp DNA fragments containing the entire PctxAB
of V. cholerae strains (n = 4) from Nepal were PCR-
amplified using zot gene (the gene preceding the ctx AB
operon)-specific forward and ctxA gene-specific reverse
primers, ZtPF and CtPR respectively [35], followed by
direct sequencing of the amplified products.
ORF content analysis of VSP-I and VSP-II region
The presence or absence of ORFs in the VSP-I and VSP-II
cluster of V. cholerae O1 isolates was examined by PCR
using primers described elsewhere [32]. V. cholerae O1
strains N16961 El Tor (ET) and O395 Classical (CL)
biotypes served as controls.
Figure 1 Map of Nepal showing the cholera affected three districts: Doti, Bajhang, and Kathmandu, 2012. Cholera affected two north-western
districts, Doti and Bajhang, including the capital city, Kathmandu, appear in red.
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Antibiotic susceptibility
Susceptibility to antibiotics was performed by disk diffu-
sion, as described by both Bauer et al. [36] and the Clinical
and Laboratory Standards Institute [37], using commercial
antibiotic discs. Nine antibiotics (Oxoid, United Kingdom)
were employed: erythromycin (E, 15 μg); gentamicin
(CN, 10 μg); trimethoprim/sulfamethoxazole (SXT, 30 μg),
tetracycline (TE, 30 μg), ampicillin (AMP, 30 μg), strepto-
mycin (S, 10 μg), azithromycin (AZM, 15 μg), nalidixic
acid (NA, 30 μg) and ciprofloxacin (CIP, 5 μg). Character-
izations of the resistance or susceptibility profiles of the
isolates were determined by measuring the inhibitory zone
and comparing it with an interpretative chart to determine
sensitivity to each antibiotic.
PCR assay for the detection of SXT element
Using PCR assays, all V. cholerae O1 strains were exam-
ined for the presence of the SXT element. The detection
of SXT was performed using primers and procedures
described previously [38].
Sequence analysis of gyrA and parC genes
The DNA sequencing of the PCR amplified genes en-
coding DNA gyrase (gyrA) and topoisomerase IV (parC)
was performed according to the previously described
procedure [39].
Pulsed-field gel electrophoresis (PFGE)
Whole agarose-embedded genomic DNA from the V.
cholerae isolates was prepared. PFGE was carried out
using a contour-clamped homogeneous electrical field
(CHEF-DRII) apparatus (Bio-Rad), according to procedures
described previously [40]. Conditions for separation were
as follows: 2 to 10s for 13 h, followed by 20 to 25 s for 6 h.
An electrical field of 6 V/cm was applied at an included
field angle of 120°. Genomic DNA of the test strains
was digested by NotI restriction enzyme (Gibco-BRL,
Gaithersburg, MD), and Salmonella enterica serovar
Braenderup was digested using XbaI, with fragments
employed as molecular size markers. Restriction fragments
were separated in 1% pulsed-field-certified agarose in
0.5X TBE (Tris-borate-EDTA) buffer. Post-electrophoresis
gel-treatment included gel-stained and de-stained. The
DNA was visualized using a UV transilluminator, and
images were digitized via a one-dimensional gel docu-
mentation system (Bio-Rad).
Image analysis
The fingerprint pattern in the gel was analyzed using a
computer software package, Bionumeric (Applied Maths,
Belgium). After background subtraction and gel normal-
ization, the fingerprint patterns were typed according
to banding similarity and dissimilarity, using the Dice
similarity coefficient and unweighted-pair group method
employing average linkage (UPGMA) clustering, as rec-
ommended by the manufacturer. The results were graph-
ically represented as dendrograms.
Results
Phenotypic and genetic characteristics
V. cholerae O1 strains (n = 28) included in this study
from 2012 diarrhea outbreaks and environmental sources
in Nepal produced translucent colonies with black center
on TTGA, and gave biochemical reactions typical of V.
cholerae. All strains reacted positively to serogroup
O1-specific antibody, but not to O139, confirming all
to be V. cholerae O1. Serological results also showed
that all V. cholerae O1 belonged to the Ogawa serotype
(Table 1). All V. cholerae strains exhibited chicken cell
agglutination (CCA), sensitivity to ET-specific phage V,
and resistance to both polymyxin B and CL specific phage
IV, confirming biotype El Tor (ET)-specific phenotypic
traits (Table 1).
The phenotypically confirmed V. cholerae O1 biotype
ET strains amplified the primers for species-specific gene
ompW, and all amplified primers specific for O biosyn-
thetic gene wbe of V. cholerae O1, but not wbf, which is
specific for serogroup O139 (Table 1). All of the V. cholerae
O1 strains isolated from cholera and from surface water
sources in Nepal amplified the primers for the cholera-
toxin gene ctxA (Table 1). In addition, all of the ctxA+
V. cholerae strains amplified the primers for biotype
ET-specific marker gene rtxC, confirming ET attributes.
All strains had tcpA, the major virulence-associated
gene of the VPI-I gene cluster, and all amplified primers
for ET-specific marker gene tcpAET, but not tcpACL. All
of the V. cholerae ET strains confirmed in this study
carried the ET biotype-specific repressor gene rstRET,
confirming that they carried ET-biotype CTX prophage,
and possessed rstC and tlc genes (Table 1).
CtxB typing by DMAMA-PCR
All V. cholerae O1 strains isolated from both clinical and
environmental sources (n = 28), including the O395 (CL),
N16961 (ET) and 2010EL-1786 (Haiti variant, ctxB geno-
type 7) were analyzed using double-mismatch amplification
mutation assay (DMAMA)-PCR technique to determine
the CTX-B genotype. As shown in Table 1, all of the ET
Biotype strains amplified the primers specific for ctxB geno-
type 7 irrespective of their source and place of isolation.
Sequencing of ctxB and tcpA
PCR-amplified genes ctxB (460 bp) and tcpA (675 bp)
from selected V. cholerae O1 strains (n = 4; one clinical
strain from each of the three districts including one
environmental strain from Kathmandu) were sequenced
and the N’-amino acid sequences determined using bio-
informatic tools. Sequencing data revealed that all of the
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Table 1 Phenotypic, genotypic and drug resistance properties of V. cholerae O1 isolated in Nepal (n = 28), 2012
Country District Year ofisolation
No. of
isolates Source Serotype wbeO1
Phenotypic properties








phage v ctxA tcpA type
ctxBa
genotype rstR type rtxC rstC tlc
Nepal Doti 2012 9 Clin Ogawa + + R R S + ET B7 ET + + + SXT, NA, S +
Kathmandu 2012 6 Env Ogawa + + R R S + ET B7 ET + + + SXT, NA, S +
Kathmandu 2012 12 Clin Ogawa + + R R S + ET B7 ET + + + SXT, NA, S +
Bajhang 2012 1 Clin Ogawa + + R R S + ET B7 ET + + + SXT, NA, S +
India 1965 O395 Clin Ogawa + - S S R + CL B1 CL - - +
Bangladesh 1971 N16961 Clin Inaba + + R R S + ET B3 ET + + +
aDetermined by double mismatch amplification mutation assay (DMAMA) PCR (Naha et al., [33]); Clin, clinical; Env, environmental; PMB, polymyxin B; R, resistant; s, sensitive; ET, El Tor; CL, classical; CCA, chicken cell




















tested V. cholerae O1 strains contained the deduced
amino acid sequence of CTXB. This is identical to that
of the CL biotype CT, having histidine and threonine
at positions 39 and 68, respectively, but an additional
sequence variation was observed in position 20, where
histidine found in CL and ET biotype CT was replaced
by asparagine (H→N) (Nucleotide accession numbers
are KJ596538, KJ596539, KJ596540 and KJ596541). The
DNA sequence and deduced amino acids matched against
the ctxB genotype 7. The ctxB sequencing data were
consistent and supported the results of DMAMA-PCR.
DNA sequencing data of the amplified tcpA gene re-
vealed the presence of a point mutation that resulted in
an amino acid substitution at position 64 (N→ S) of
the deduced peptide (accession numbers are KJ596546,
KJ596547, KJ596548 and KJ596549).
The promoter sequence of ctxABclass operon
Analysis of the promoter sequences of the randomly
selected Nepalese V. cholerae O1 strains isolated in
2012 revealed that they contained four copies of heptamer
repeat sequences in the PctxAB regions (accession numbers
are KJ596554, KJ596555, KJ596556 and KJ596557) irre-
spective of their source of isolation. This indicates that
the CT regulatory regions of these strains are like those
of canonical El Tor strains and dissimilar to those of
classical strains, which usually carry seven to eight such
repeats [38].
VSP Islands
All Nepalese V. cholerae O1 examined in this study carried
all the tested ORFs of the VSP-I genomic island region.
However, all strains lacked the VSP-II genomic island ORFs
VCO498, VCO502, VCO504 and VCO511 (Table 2).
Antibiotic susceptibility assay
Antibiotic susceptibility assay revealed that all of the 28
tested V. cholerae O1 strains isolated in 2012 from the
three districts of Nepal, irrespective of their source and
place of isolation, were multi-drug resistant with resistance
to NA, SXT, and S. However, all strains were sensitive to
AZM, TE, AMP, CN, E, and CIP (Table 1).
Detection of SXT element
All of the V. cholerae strains (n = 28) amplified the primer
for the SXT gene, a mobile genetic element carrying
multi-drug resistance gene cassettes in bacteria (Table 1).
Sequencing of gyrA and parC
Sequencing of gyrA and parC of V. cholerae O1 strains
(n = 4) representing three districts of Nepal, including
both clinical and environmental sources of Kathmandu,
detected one point mutation in each; in gyrA serine was
substituted by isoleucine at position 83 (accession numbers
are KJ596542, KJ596543, KJ596544 and KJ596545), and
in parC serine was substituted by leucine at position 85
(accession numbers are KJ596550, KJ596551, KJ596552
and KJ596553).
PFGE and cluster analysis
The PFGE of NotI-digested genomic DNAs of the V.
cholerae O1 strains yielded 20 to 23 fragments (Figure 2)
(Data available from the Dryad Digital Repository: doi:10.
5061/dryad.600nd), and their molecular sizes ranged from
20.5 to 350 kb. The PFGE pattern of all the Nepalese strains
irrespective of their source and place of isolation matched
both with each other, and with that of the altered El
Tor PFGE pattern in the number and position of the
DNA fragments, suggesting genetic homogeneity .
In order to understand the clonal link between the V.
cholerae O1 strains associated with cholera outbreaks
in Doti, Kathmandu, and Bajhang, cluster analysis was
performed by dendogram using the PFGE (NotI) images
of the Nepalese V. cholerae O1 strains, together with
PFGE (NotI) images of representative V. cholerae O1
strains isolated in Bangladesh (2010) and Haiti (2010),
which were available in our soft database. All of the
Nepalese strains were clonal as they shared the same
cluster showing 100% similarity, and were related closely
with representative V. cholerae O1 altered El Tor strains
isolated in Bangladesh and Haiti.
Discussion
This study presents microbiological and molecular data
on V. cholerae isolated from 2012 Nepal cholera and
surface water sources showing the transmission of a
highly clonal, multi-drug resistant V. cholerae O1, which
was associated with simultaneous cholera outbreaks
occurring in Kathmandu and the remote villages of the
western districts of Doti and Bajhang, Nepal. The study
also revealed very close clonal relationships between
the Nepalese V. cholerae O1 strains with those from
Bangladesh and Haiti isolated in 2010.
The conventional culture, biochemical, and serological
test results confirmed that both clinical and environmental
V. cholerae isolates belonged to serogroup O1 and serotype
Ogawa. The microbiological test results were comple-
mented by the molecular data obtained from PCR assays
performed for the amplification of V. cholerae species-
specific gene ompW [27], genes ctxA encoding subunit
A of cholera toxin (CTX), and wbe encoding serogroup
O1-specific antigenic polysaccharides [28]. These results
confirmed that all of the V. cholerae isolates were toxigenic
and belonged to serogroup O1. The phenotypic character-
istics, together with the presence of biotype specific
marker genes, such as rtxC, rstC, tcpAET, rstRET, and
ctxBCL, confirmed that all of the V. cholerae O1 strains
occurring in surface water and associated with the 2012
Dixit et al. BMC Infectious Diseases 2014, 14:392 Page 6 of 11
http://www.biomedcentral.com/1471-2334/14/392






District Source VCO175 VCO178 VCO180 VCO183 VCO185 VCO490 VCO493 VCO498 VCO502 VCO504 VCO511 VCO512 VCO513 VCO514 VCO515 VCO516 VCO517
2012 9 Doti Clin + + + + + + ND - - - - ND + + + ND +
2012 6 Kathmandu Env + + + + + + ND - - - - ND + + + ND +
2012 12 Kathmandu Clin + + + + + + ND - - - - ND + + + ND +
2012 1 Bajhang Clin + + + + + + ND - - - - ND + + + ND +
1965 O395 Clin - - - - - - - - - - - - - - - - +
1971 N16961 Clin + + + + + + + + + + + + + + + + +




















cholera outbreaks in Nepal were biotype El Tor posses-
sing the ctxB marker gene of classical biotype. This
important data identified all strains as altered El Tor,
first described in Bangladesh in 2006 [7,11].
Although treatment of cholera involves a course of
effective antibiotics, together with appropriate oral or
intravenous rehydration fluid(s) [41], antibiotic therapy
world-wide has faced with challenges related to the rapid
emergence and spread of multi-drug resistant (MDR) V.
cholerae strains resistant to atibiotics, such as TE, AMP,
kanamycin (KN), S, SXT, NA, E, and most recently, to
CIP and norfloxacin (NOR) [17,21,42,43]. In Nepal, at
least three different resistance phenotypes of V. cholerae
were previously reported to be in circulation [24]. A recent
study reported temporal variation in drug resistance
patterns of V. cholerae associated with cholera in Nepal
between 2007 and 2010 [25]. In the present study, V.
cholerae O1 associated with diarrheal outbreaks in
Nepal, including those isolated from natural surface
water samples, were MDR showing resistance towards
SXT, NA, and S, suggesting that drug resistance patterns
can change temporally, and spatially, and thus require
continuous monitoring in order to select an effective drug
of choice at any given time.
In V. cholerae, multi-drug resistance was shown to be
attributed to lateral acquisition of self-transmissible gen-
etic element designated SXT, carrying multiple antibiotic-
resistance markers [44]. All V. cholerae strains tested in
the present Nepalese study were MDR and likewise, all
had the SXT element, presumably carrying MDR marker
genes in their genome, a fact that appears to be in line
with their consistent resistance towards trimethoprim-
sulfamethxazole. Resistance to fluoroquinolones such as
NA is mostly associated with genes encoding gyrase
(gyrA and gyrB) and topoisomerase IV (parC and parE).
DNA sequencing of the gyrA and parC of the Nepalese
V. cholerae strains suggests a similar molecular basis
for quinolone resistance, as a single point mutation in
each of the genes resulted in amino acid switching from
Serine to Isoleucine at 83 position, and Serine to Leucine
at 85 position, respectively, as found in the quinolone
resistant V. cholerae associated with cholera in Africa
[20], India [39], and Haiti [45].
The polymorphism of ctxB gene-encoding cholera
toxin (CT) subunit B and the corresponding amino acid
substitution was first reported in the early 1990’s [34].
Subsequent investigation of the ctxB gene sequence
revealed the presence of eleven distinct genotypes in
different serogroups of V. cholerae [46]. Genotypes 1,
2, 3, 7, 10, and 11 were found in serogroup O1 strains,
genotypes 3, 4, 5, and 6 were found in serogroup O139
strains, and genotypes 8 and 9 were found only in
Figure 2 Dendrogram showing genomic fingerprints of V. cholerae O1 strains isolated in Nepal in 2012. Genomic fingerprinting of multi-drug
resistant V. cholerae O1 El Tor strains isolated from 2012 diarrhea outbreaks in three districts (Doti, Bajhang, and Katmandu) of Nepal. Dendrogram was
constructed by Dice similarity coefficient and UPGMA clustering method by using pulsed-field gel electrophoresis (PFGE) images of NotI- restriction
digested genomic DNA of the tested Nepalese V. cholerae strains; PFGE images of contemporary V. cholerae O1 El Tor strains from Haiti and Bangladesh,
including El Tor reference strain N16961 were also included. The scale bar at the top (left) indicates similarity coefficient. The banding patterns and
the similarity coefficient revealed 100% similarity for all the tested Nepalese, Haitian, and Bangladeshi V. cholerae strains included in the dendrogram,
suggesting° high level of clonal relatedness (Data available from the Dryad Digital Repository: doi:10.5061/dryad.600nd).
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serogroups O27 and O37 [46]. A previous study
showed the presence of two different ctxB genotypes,
namely 1 and 7, among V. cholerae associated with chol-
era in Nepal between 2007 and 2010 [25]. In the present
study, ctxB genotype 7 was confirmed for all 28V. cho-
lerae O1 strains isolated in 2012 from three districts of
Nepal. Data presented in this study provide ample evi-
dence of genetic switching from ctxB genotype 1 to 7
in Nepal, a phenomenon seen in 2007 and 2008 for V.
cholerae causing endemic cholera in India [47] and
Bangladesh [48], respectively. The global dissemination of
ctxB genotype 7 has been growing with reports of the
genotype in the West African countries of Nigeria and
Cameroon, as well as in Haiti [17,20].
The toxin co-regulated pilus (TCP), an essential colon-
ization factor of V. cholerae [49] that also serves as a
receptor for CTX-Φ [44], is a homopolymer of the
major pilus protein, TcpA pilin [49] encoded by tcpA.
The DNA sequence of tcpA differs slightly at the C-
terminal domain for classical and El Tor biotype strains
[3]. In the present study, DNA sequencing and the
deduced amino acid sequences of TcpA of V. cholerae
O1 El Tor strains associated with cholera outbreaks in
Nepal (2012) differed from the El Tor reference strain
N16961 due to a mutation at the amino acid position
64 (Asparagine→ Serine). This change may be subtle
and it is not known whether such genetic switching of
the tcpA gene has any epidemiological impact on V.
cholerae causing endemic cholera in Nepal. Nonetheless,
a change of amino acid at position 64 of TcpA was first
reported in the V. cholerae serogroup O1 biotype El
Tor strain associated with cholera in Bangladesh [50].
This was followed by reports from Haiti [51], suggesting
that this genotype is spreading globally.
ToxR is a global transcriptional regulator protein respon-
sible for virulence gene expression, and toxR sequence
repeats (TTTTGAT) located between CTX prophage
genes zot and ctxA are essential for ToxR binding and
activation of the ctxAB promoter [52]. The Nepalese V.
cholerae O1 strains contained four copies of such repeats
(data not shown), while five copies were found among
the El Tor variant of V. cholerae associated with cholera
in Haiti [17,45]. These are less than the seven copies
that were reported for the classical biotype strains of V.
cholerae O395.
The VSP-I gene cluster encompasses a 16 kb region
from VC0175 to VC0185, and most of the genes encode
hypothetical or conserved proteins with no known func-
tion. On the other hand, the VSP-II region is a ~27 kb
region that encompasses VC0490–VC0516 [29]. These
two clusters are unique to the El Tor strains of the seventh
pandemic. The Nepalese V. cholerae O1strains carried
intact VSP-I but harbored a variant VSP-II lacking the
ORFs 498–511 of the VSP-II genomic island region, which
was first reported from a V. cholerae strain (CIRS101)
associated with cholera in Bangladesh [53] and Haiti [45].
A recent MLVA-based study carried out with V. cholerae
O1 strains associated with cholera between 2007 and 2010
showed the circulation of four different groups of altered
V. cholerae O1 El Tor strains in Western Nepal including
Butwal and Kathmandu [25]. The molecular basis and
epidemiological significance of such genetically divergent
V. cholerae O1 altered El Tor remains an interesting area
to explore. However,V. cholerae O1 associated with cholera
outbreaks in the three Nepalese districts proved to be
highly clonal, since all of the strains had an indistinguish-
able PFGE (Not-I) banding pattern irrespective of their
source of isolation, reflecting high genetic homogeneity in
the V. cholerae population. The PFGE pattern generated
by the V. cholerae O1 strains in this study also matched
with the pattern reported for V. cholerae O1 associated
with cholera outbreaks in Bangladesh and Haiti, suggest-
ing that closely related multi-drug resistant strains are
undergoing global dissemination.
Conclusion
In conclusion, this study presents data on the transmis-
sion of a multi-drug resistant V. cholerae showing iden-
tical PFGE pattern in three districts (Doti, Bajhang, and
Kathmandu) of Nepal during the 2012 diarrhea outbreaks.
Considering the changing climate and increasing global
burden of cholera, and the emergence and spread of
new hyper-infective variants of V. cholerae [16], regular
surveillance of V. cholerae outbreaks is highly recom-
mended for monitoring the distribution, clonal type
and evolution of the pathogen, for effective cholera
management in Nepal and elsewhere.
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